Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1